Company Molecure S.A.

Equities

MOC

PLONCTH00011

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Warsaw S.E. Other stock markets 16:55:42 15/05/2024 BST			5-day change	1st Jan Change
14.72 ^PLN	-4.29%		+1.66%	-24.51%

03-22	Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis	CI
01-16	Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I	CI

Oncoarendi Therapeutics SA is a Poland-based biopharmaceutical company . The Company is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The Company's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The Company has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.

Number of employees: 109

PLN in Million	2022	Weight	2023	Weight	Delta
Small Molecule Chemicals 100.0 %	2	100.0 %	1	100.0 %	-18.85%

PLN in Million	2022	Weight	2023	Weight	Delta
Poland 100.0 %	2	100.0 %	1	100.0 %	-18.85%

Managers	Title	Age	Since
Marcin Jan Szumowski CEO	Chief Executive Officer	-	30/11/12
Slawomir Piotr Broniarek DFI	Director of Finance/CFO	50	31/03/15
Zbigniew Zaslona CTO	Chief Tech/Sci/R&D Officer	-	-
Samson Fung CTO	Chief Tech/Sci/R&D Officer	-	26/01/22
Marta Dudek CTO	Chief Tech/Sci/R&D Officer	-	31/08/21
Anna Bajera CTO	Chief Tech/Sci/R&D Officer	-	-
Marta Borkowska COO	Chief Operating Officer	-	31/12/12
Pawel Dobrzanski PRN	Corporate Officer/Principal	-	-
Agnieszka Rajczuk-Szczepanska HRO	Human Resources Officer	53	-

Members of the board	Title	Age	Since
Tomasz Piec BRD	Director/Board Member	-	29/06/21
Paul van der Horst CHM	Chairman	-	13/01/22
Nancy van Osselaer BRD	Director/Board Member	-	13/01/22
Pawel Trawkowski BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	16,836,000	10,627,037 ( 63.12 %)	0	63.12 %

Name	Equities	%	Valuation
MS Galleon GmbH 20.00 %	3,367,200	20.00 %	12 M zł
Marcin Jan Szumowski 6.355 %	1,070,000	6.355 %	4 M zł
Nationale-Nederlanden PTE SA 5.019 %	845,000	5.019 %	3 M zł
Black Forest SICAV-SIF SCA 4.947 %	832,800	4.947 %	3 M zł
ESALIENS TFI SA 2.671 %	449,750	2.671 %	2 M zł
Allianz Polska TFI SA 1.947 %	327,839	1.947 %	1 M zł
Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SA 0.3276 %	55,160	0.3276 %	198 485 zł
BNP Paribas Polska TFI SA 0.0534 %	8,992	0.0534 %	32 356 zł
Altus SA (Investment Management) 0.0416 %	7,000	0.0416 %	25 188 zł
Rockbridge TFI 0.0359 %	6,039	0.0359 %	21 730 zł

Molecure SA

Zwirki i Wigury 101

02-089, Warsaw

+48 225 52 67 24

http://molecure.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.38 PLN

Average target price

34 PLN

Spread / Average Target

+121.07%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MOLECURE S.A.	-24.51%	65.58M
VERTEX PHARMACEUTICALS INCORPORATED	+7.63%	111B
REGENERON PHARMACEUTICALS, INC.	+11.47%	106B
BIONTECH SE	-12.31%	22.24B
ARGENX SE	+0.44%	21.25B
GENMAB A/S	-4.18%	18.97B
WUXI APPTEC CO., LTD.	-37.85%	18.52B
BEIGENE, LTD.	-8.74%	16.81B
SAREPTA THERAPEUTICS, INC.	+38.56%	12.54B
LEGEND BIOTECH CORPORATION	-24.32%	8.09B

Bio Therapeutic Drugs